Fig. 4: BLI, FMI, and CTA in orthotopic liver tumor-bearing mice on day 20 post-drug treatment (n = 3). | Experimental & Molecular Medicine

Fig. 4: BLI, FMI, and CTA in orthotopic liver tumor-bearing mice on day 20 post-drug treatment (n = 3).

From: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

Fig. 4

a In vivo BLI and FMI of control and sorafenib and apatinib treatment groups at the time points of pretreatment and 0, 4, 8, 12, 24, and 48 h post-treatment of AngioSense 750 EX. b Ex vivo white light imaging, BLI, and FMI livers from mice and H&E staining of liver tumor specimens at 48 h post-treatment with AngioSense 750 EX. Black arrows indicate tumor tissues. c The 3D CTA in the control and sorafenib and apatinib treatment groups 15 min after Fenestra VC injection. The red dotted line denotes tumor blood vessel areas

Back to article page